*Department of Pathology, Westchester Medical Center/New York Medical College, Valhalla ‡James J Peters VA Medical Center at Bronx and Icahn School of Medicine at Mount Sinai §Mount Sinai Medical Center, New York, NY ∥Department of Pathology, Northwestern University, Chicago, IL †Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD.
Am J Surg Pathol. 2015 Jan;39(1):127-31. doi: 10.1097/PAS.0000000000000305.
Nested variant of urothelial carcinoma (NVUC) is an uncommon variant with minimally atypical cytology, which may overlap with benign urothelial lesions such as von Brunn nests, cystitis cystica, cystitis glandularis, and nephrogenic adenoma. Because of the tumor's deceptively bland appearance, these cancers can potentially be misdiagnosed as benign lesions, leading in some cases to a significant delay in correct diagnosis and appropriate treatment. Prior studies suggest that Ki67 and p53 are useful markers in distinguishing NVUC from benign lesions. However, the overlap in the rates of immunoreactivity has prevented pathologists from using these markers as reliable adjunct markers in differentiating NVUC from mimickers. In addition, large nested variant urothelial carcinoma (LNVUC), a relatively new entity, shares features of both the NVUC and papillary urothelial carcinomas with an inverted growth pattern. They also mimic benign lesions, such as proliferation of von Brunn nests and inverted urothelial papilloma. With the recent demonstration of a strong association of TERT promoter mutations and urothelial carcinoma, we hypothesized that TERT promoter mutations would be a useful marker to distinguish NVUC and LNVUC from other benign urothelial lesions. We have therefore sequenced the TERT promoter region of 20 cases of NVUC, 10 cases of LNVUC, 5 cases of von Brunn nests, 3 cases of cystitis cystica, 3 cases of cystitis glandularis, and 3 cases of nephrogenic adenoma. We found that 17 of 20 cases of NVUC and 8 of 10 cases of LNVUC had TERT promoter mutation: C228T; no mutation was found in any of the benign mimickers (0/14). This result strongly suggests that TERT promoter mutation is a useful adjunct biomarker to distinguish NVUC and LNVUC from benign mimickers.
尿路上皮癌的巢状变异型(NVUC)是一种罕见的具有最小非典型细胞学的变异型,其可能与良性尿路上皮病变重叠,如 von Brunn 巢、囊性膀胱炎、腺性膀胱炎和肾源性腺瘤。由于肿瘤具有欺骗性的温和外观,这些癌症可能被误诊为良性病变,在某些情况下导致正确诊断和适当治疗的显著延迟。先前的研究表明,Ki67 和 p53 是区分 NVUC 与良性病变的有用标志物。然而,免疫反应率的重叠使得病理学家无法将这些标志物用作区分 NVUC 与模拟物的可靠辅助标志物。此外,大型巢状变异型尿路上皮癌(LNVUC)是一种相对较新的实体,具有 NVUC 和乳头状尿路上皮癌的特征,具有倒置生长模式。它们也模仿良性病变,如 von Brunn 巢和倒置尿路上皮乳头瘤的增生。最近证明 TERT 启动子突变与尿路上皮癌有很强的关联,我们假设 TERT 启动子突变将是区分 NVUC 和 LNVUC 与其他良性尿路上皮病变的有用标志物。因此,我们对 20 例 NVUC、10 例 LNVUC、5 例 von Brunn 巢、3 例囊性膀胱炎、3 例腺性膀胱炎和 3 例肾源性腺瘤的 TERT 启动子区域进行了测序。我们发现 20 例 NVUC 中有 17 例和 10 例 LNVUC 中有 8 例存在 TERT 启动子突变:C228T;在任何良性模拟物中均未发现突变(0/14)。这一结果强烈表明 TERT 启动子突变是区分 NVUC 和 LNVUC 与良性模拟物的有用辅助生物标志物。